1st Optimal Prescription and Intake Process: What to Expect

What Is 1st Optimal and Is It a Legitimate Practice?

1st Optimal operates as a cash-pay concierge telehealth service with a clinical focus on performance and longevity medicine. Prescriptions are issued by licensed physicians or nurse practitioners, which places the brand within the same regulatory framework as any outpatient prescriber in the United States.

Legitimacy in telehealth turns on three questions: Are prescriptions written by licensed providers? Are labs required before controlled substances are dispensed? Are compounding pharmacies accredited? By each of those criteria, 1st Optimal clears the minimum bar for a compliant practice.

The broader performance-and-longevity telehealth category has grown sharply. A 2023 JAMA Internal Medicine analysis found that testosterone prescriptions via telehealth platforms rose more than 400% between 2019 and 2022, highlighting both patient demand and the need for careful clinical oversight. (1)

How It Differs From Standard Primary Care

Standard primary care typically applies population-level reference ranges. A total testosterone of 300 ng/dL sits at the low end of the 264 to 916 ng/dL reference interval published in the Endocrine Society's 2018 clinical practice guideline, and many PCPs decline to treat at that level. (2) Concierge performance practices often aim for a functional target, typically 700 to 900 ng/dL total testosterone, based on symptomatic response rather than reference-range position alone.

That distinction matters clinically. The T Trials (N=790 men aged 65 and older) demonstrated that testosterone treatment raised hemoglobin by a mean of 0.8 g/dL and improved sexual function scores versus placebo, effects that were statistically significant at P<0.001. (3) The T Trials do not prove that optimizing testosterone above the reference floor produces those same benefits in younger, asymptomatic men, which is an honest limitation any performance clinic should disclose.

What "Concierge" Means for Access

The concierge label means patients pay a direct fee rather than billing insurance. That removes prior-authorization delays but also means no cost-sharing. For patients whose insurance covers none of these therapies anyway, the out-of-pocket difference may be smaller than assumed.

The 1st Optimal Intake and Prescription Process, Step by Step

Understanding the sequence helps patients arrive prepared and reduces the time from enrollment to first prescription.

Step 1: Online Intake Form

Patients complete a structured health history questionnaire covering symptoms, prior diagnoses, current medications, and goals. The intake typically takes 15 to 20 minutes. Accurate symptom reporting here directly shapes which lab panel the provider orders, so underreporting symptoms is counterproductive.

Step 2: Lab Panel

Labs are required before any prescription is written. A standard male hormone panel at most performance practices includes total testosterone, free testosterone (calculated or direct), LH, FSH, SHBG, estradiol, CBC, CMP, PSA (for men over 40), and thyroid markers (TSH, free T3, free T4). Female panels typically add progesterone and, for perimenopausal patients, AMH.

The Endocrine Society recommends measuring testosterone "in the morning on at least two separate occasions" before diagnosing hypogonadism, and a compliant practice should either require two draws or document why a single draw was sufficient. (2)

Patients can use local LabCorp or Quest draw sites. Turnaround is generally 24 to 72 hours. Some protocols include at-home finger-stick kits, though venipuncture remains the gold standard for testosterone assays.

Step 3: Clinician Consultation

A licensed provider reviews the labs and intake alongside the patient in a video or phone consultation. This is the point at which a diagnosis (hypogonadism, hypothyroidism, metabolic syndrome) is or is not confirmed and where a protocol is proposed.

Patients should arrive with three specific questions ready: What is my diagnosis and what guideline supports treatment at my lab values? What monitoring schedule will you use? What are the stopping criteria if markers move in the wrong direction?

Step 4: Protocol and Prescription

Protocols vary by condition. A typical male TRT protocol might include testosterone cypionate 100 to 200 mg per week (subcutaneous or intramuscular injection), anastrozole 0.25 to 0.5 mg twice weekly if estradiol rises above 40 pg/mL, and human chorionic gonadotropin (hCG) or enclomiphene if fertility preservation is a goal. Female HRT protocols commonly include estradiol patches or cream and micronized progesterone 100 to 200 mg nightly.

Step 5: Pharmacy Fulfillment

Prescriptions go to compounding pharmacies or to standard retail pharmacies depending on whether an FDA-approved product exists for the prescribed form and dose. Testosterone cypionate is available as Depo-Testosterone (Pfizer) in FDA-approved vials; many practices nevertheless use compounded versions for dose flexibility. The FDA's 2023 guidance on bulk drug substances clarifies that 503A pharmacies may compound testosterone if the commercial product is not clinically appropriate for a specific patient. (4)

Step 6: Follow-Up and Monitoring

Labs are typically rechecked at 6 to 8 weeks post-initiation, then every 3 to 6 months once stable. The Endocrine Society guideline states hematocrit should be measured at 3 to 6 months and annually thereafter, with dose reduction or phlebotomy if hematocrit exceeds 54%. (2)

What Does 1st Optimal Prescribe? The Core Protocol Categories

Performance-and-longevity practices typically cluster prescriptions into four categories. Each carries a different evidentiary weight.

Testosterone Replacement Therapy (TRT)

TRT is the best-supported intervention in this category. The 2018 Endocrine Society guideline recommends testosterone therapy for men with classic hypogonadism (two morning total testosterone levels <300 ng/dL plus symptoms). (2) The T Trials showed meaningful improvements in sexual function, mood, and bone mineral density. The TRAVERSE trial (N=5,204), published in the New England Journal of Medicine in 2023, found no statistically significant increase in major adverse cardiovascular events (MACE) at 33 months of follow-up in men aged 45 to 80 with hypogonadism and pre-existing cardiovascular disease or high risk, addressing a safety concern that had clouded the field since the 2010 Basaria trial. (5)

Testosterone is available as injections, gels (AndroGel, Testim), patches, pellets, and buccal tablets. Injections remain the most cost-effective for most patients.

Thyroid Optimization

Many performance practices supplement standard TSH testing with free T3 and reverse T3 measurements and may add T3 (liothyronine) to levothyroxine monotherapy in patients who remain symptomatic despite a normal TSH. The American Thyroid Association's 2014 guideline states that combination T4/T3 therapy "may be appropriate for certain patients" who do not feel well on T4 alone, though it stops short of a broad recommendation. (6)

A 2019 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (9 RCTs, N=1,216) found no significant quality-of-life advantage for combination T4/T3 over T4 monotherapy in hypothyroid patients. (7) Patients should weigh that evidence against the clinical experience their provider describes.

GLP-1 Receptor Agonists

GLP-1 agents like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have strong Phase III data behind them. In SURMOUNT-1 (N=2,539), tirzepatide 15 mg produced a 20.9% mean weight reduction at 72 weeks versus 3.1% placebo. (8) In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% placebo. (9)

Compounded semaglutide became widely available during the FDA-designated shortage period. The FDA removed semaglutide from the shortage list in February 2025, which means 503A pharmacies may no longer legally compound it for most patients. Practices must prescribe FDA-approved branded products or demonstrate a documented clinical reason for compounding. Patients starting GLP-1 therapy in 2025 should confirm their pharmacy's compliance status.

Peptides

Peptides are where evidentiary quality drops significantly. Compounds like BPC-157, CJC-1295, ipamorelin, and TB-500 are popular in performance circles but lack FDA-approved indications, large RCTs, and long-term safety data.

The FDA issued a statement in 2023 clarifying that BPC-157 is not an approved drug and may not be used as a bulk drug substance in compounding. (10) Growth hormone secretagogues (CJC-1295, ipamorelin) act on the GHRH receptor to raise IGF-1. A 2019 systematic review in the Journal of Clinical Endocrinology and Metabolism found that growth hormone therapy in healthy adults of normal stature produced small lean-mass gains but no performance benefit and increased carpal tunnel and edema rates. (11) Patients considering peptide protocols should request specific evidence from their provider rather than accepting general wellness claims.

How Much Does 1st Optimal Cost?

Cash-pay concierge practices do not publish uniform pricing because protocols vary by complexity. The following estimates are representative for the category based on publicly available information from comparable platforms.

| Protocol Component | Estimated Monthly Cost | |---|---| | TRT (testosterone cypionate injections) | $40 to $80 | | Anastrozole (if needed) | $15 to $30 | | hCG or enclomiphene | $60 to $120 | | GLP-1 (branded semaglutide Wegovy) | $900 to $1,350 (without insurance) | | GLP-1 (compounded, where legal) | $200 to $450 | | Thyroid (levothyroxine + liothyronine) | $20 to $50 | | Peptide protocols | $150 to $400 | | Provider/membership fee | $99 to $199 per month |

Total monthly spend for a patient on TRT plus a basic peptide protocol might range from $300 to $600. Adding a GLP-1 agent pushes that to $500 to $1,000 or higher for branded products.

HSA and FSA funds can generally be applied to prescription medications and provider visits. Membership fees may or may not qualify depending on how the platform codes the charge; patients should verify with their plan administrator.

1st Optimal vs. Alternative Platforms

The performance-and-longevity telehealth space includes several direct competitors. Comparing them on four dimensions helps patients choose rationally rather than based on marketing language.

Lab Requirements

Stricter lab requirements generally indicate a more clinically conservative approach. Platforms that offer "no labs required" testosterone prescriptions are operating outside Endocrine Society guidance. Both 1st Optimal and competitors like Defy Medical require labs before prescribing. Direct-to-consumer testosterone services that skip labs should be approached with caution.

Provider Type

Physician-only practices differ from NP/PA-led practices in supervising physician availability and state-specific scope-of-practice rules. Neither model is inherently inferior, but patients with complex comorbidities (cardiovascular disease, prostate cancer history, active fertility goals) benefit from physician-level oversight.

Compounding Pharmacy Standards

PCAB accreditation (the Pharmacy Compounding Accreditation Board) is the relevant quality standard for 503A pharmacies. Practices that route prescriptions to PCAB-accredited facilities offer a higher degree of quality assurance for sterile compounded injectables. Patients should ask which pharmacy will fill their prescription and verify its accreditation status directly at pcab.pharmacy.

Protocol Flexibility

Some platforms offer fixed protocol tiers. Others, including concierge models like 1st Optimal, adjust doses based on labs at each monitoring visit. Adjustable protocols add complexity but generally produce better clinical outcomes for TRT. A 12-month prospective study published in the Journal of Urology (N=120) found that men on flexible-dose TRT reached therapeutic testosterone targets in 78% of cases versus 52% on fixed-dose protocols. (12)

Evidence Quality: What the Research Actually Supports

Not every service a performance practice offers carries the same evidence weight. Patients benefit from understanding this gradient before spending money.

Strong evidence (multiple RCTs, guideline endorsement): TRT for confirmed hypogonadism; GLP-1 agents for obesity or type 2 diabetes.

Moderate evidence (observational data, small RCTs, guideline acknowledgment): Combination T4/T3 for symptomatic hypothyroidism on T4 monotherapy; DHEA supplementation in adrenal insufficiency.

Limited evidence (mechanistic data, case series, no large RCTs): Most peptide protocols; high-dose vitamin D beyond correction of deficiency; methylene blue; low-dose naltrexone for performance.

The American Association of Clinical Endocrinology (AACE) 2022 diabetes and obesity guidelines note that lifestyle intervention combined with pharmacotherapy produces durable weight loss, but that combination hormonal optimization protocols for weight loss in eugonadal individuals lack sufficient evidence for routine recommendation. (13)

Patients should ask their 1st Optimal provider to classify each prescribed agent by evidence tier. A provider unwilling to do that deserves scrutiny.

Red Flags to Watch for in Any Performance Telehealth Practice

A few specific patterns should prompt patients to pause.

Prescribing testosterone without two morning lab draws is a deviation from Endocrine Society guidance. Skipping PSA testing in men over 40 before starting TRT violates the same guideline. Offering peptides like BPC-157 as compounded injectables after the FDA's 2023 clarification of its bulk substance status may expose the practice to regulatory action and patients to quality-uncertain products.

The FDA's MedWatch system allows patients and providers to report adverse events from compounded products. (14) Documenting and reporting adverse outcomes is a patient right.

Prices that seem unusually low for compounded injectables, such as below $30 per month for a testosterone cypionate vial, sometimes indicate pharmacy quality concerns. The USP chapter 797 sterile compounding standards require specific beyond-use dating, environmental monitoring, and sterility testing that have real cost floors. (15)

Clinical Checklist Before Starting Any Protocol at 1st Optimal

A short list of actions reduces risk and improves outcomes for any patient entering a performance telehealth program.

1. Obtain and keep personal copies of all lab results.
2. Confirm the prescribing provider's license at your state medical board before the first consultation.
3. Ask which pharmacy will fill the prescription and verify its PCAB or state board accreditation.
4. Request a written monitoring schedule with specific lab targets and dose-adjustment criteria.
5. Disclose all supplements and over-the-counter medications, since several (zinc, DHEA, biotin) directly interfere with testosterone and thyroid assay accuracy.
6. If prescribed a GLP-1 agent, confirm the product is FDA-approved or that your provider has documented a patient-specific reason for compounding.

The Endocrine Society's patient education resource on hypogonadism states: "Men with testosterone deficiency should be treated only if they have both low testosterone on at least two morning measurements and symptoms or signs that could be attributed to testosterone deficiency." (2) That standard should apply regardless of which platform a patient uses.